Thyrocare Technologies Ltd
THYROCAREThyrocare Technologies Ltd
THYROCAREPrice Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
56.48 | 8.31 | — |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
51.91 | 6.64 | 0.47% |
Forecast & Ratings
Detailed Forecast from 2 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Thyrocare Technologies Limited is a diagnostic chain company which offers a range of medical diagnostic tests and profiles of tests that center on early detection and management of disorders and diseases.
Peers
Compare with peersApollo Hospitals Enterprise Ltd
Max Healthcare Institute Ltd
Fortis Healthcare Ltd
Dr. Lal PathLabs Ltd
Global Health Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ cr.
All values in ₹ cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 247.51 | 316.63 | 379.32 | 413.52 | 441.44 | 507.05 | 618.11 | 536.27 | 581.64 | 606.39 | ||||||||||
Raw Materials | 69.68 | 81.78 | 94.61 | 110.79 | 117.17 | 163.86 | 170.57 | 163.03 | 166.98 | 448.91 | ||||||||||
Power & Fuel Cost | 5.32 | 6.35 | 6.68 | 7.77 | 8.69 | 7.64 | 8.40 | 10.70 | 10.15 | |||||||||||
Employee Cost | 25.70 | 32.00 | 35.34 | 43.35 | 48.92 | 58.07 | 61.13 | 106.15 | 107.86 | |||||||||||
Selling & Administrative Expenses | 28.89 | 46.14 | 49.57 | 59.27 | 44.48 | 42.16 | 45.47 | 52.69 | 73.23 | |||||||||||
Operating & Other expenses | 17.33 | 50.17 | 27.59 | 27.50 | 48.01 | 51.70 | 67.74 | 71.57 | 74.90 | |||||||||||
EBITDA | 100.59 | 100.19 | 165.53 | 164.84 | 174.17 | 183.62 | 264.80 | 132.13 | 148.52 | 157.48 | ||||||||||
Depreciation/Amortization | 18.24 | 18.05 | 20.10 | 26.17 | 31.91 | 30.28 | 33.87 | 38.71 | 47.01 | 48.54 | ||||||||||
PBIT | 82.35 | 82.14 | 145.43 | 138.67 | 142.26 | 153.34 | 230.93 | 93.42 | 101.51 | 108.94 | ||||||||||
Interest & Other Items | 0.55 | 0.46 | 0.44 | 0.61 | 1.85 | 0.87 | 3.21 | 4.83 | 5.53 | 4.31 | ||||||||||
PBT | 81.80 | 81.68 | 144.99 | 138.06 | 140.41 | 152.47 | 227.72 | 88.59 | 95.98 | 104.63 | ||||||||||
Taxes & Other Items | 30.00 | 38.83 | 51.71 | 52.92 | 52.01 | 39.32 | 51.58 | 24.10 | 25.22 | 26.99 | ||||||||||
Net Income | 51.80 | 42.85 | 93.28 | 85.14 | 88.40 | 113.15 | 176.14 | 64.49 | 70.76 | 77.64 | ||||||||||
EPS | 9.94 | 7.98 | 17.36 | 15.99 | 16.74 | 21.41 | 33.30 | 12.19 | 13.37 | 14.66 | ||||||||||
DPS | 10.00 | 10.00 | 10.00 | 20.00 | 5.00 | 25.00 | 15.00 | 18.00 | 0.00 | 0.00 | ||||||||||
Payout ratio | 1.01 | 1.25 | 0.58 | 1.25 | 0.30 | 1.17 | 0.45 | 1.48 | 0.00 | 0.00 |
Company Updates
Peers & Comparison
Health CareHospitals & Diagnostic Centres
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Thyrocare Technologies Ltd | 61.97 | 8.31 | — |
Apollo Hospitals Enterprise Ltd | 114.66 | 14.07 | 0.22% |
Max Healthcare Institute Ltd | 89.33 | 11.24 | 0.15% |
Fortis Healthcare Ltd | 77.64 | 5.43 | 0.16% |
Price Comparison
Compare THYROCARE with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
High Pledged Promoter Holding
A significant proportion of promoter holdings is pledged
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Thyrocare Technologies Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
Nippon India Small Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 3.8731% | Percentage of the fund’s portfolio invested in the stock 0.28% | Change in the portfolio weight of the stock over the last 3 months 0.08% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 115/231 (+39) |
Nippon India Pharma Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 3.4705% | Percentage of the fund’s portfolio invested in the stock 1.76% | Change in the portfolio weight of the stock over the last 3 months 0.24% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 24/36 (0) |
Quant Small Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 1.8718% | Percentage of the fund’s portfolio invested in the stock 0.32% | Change in the portfolio weight of the stock over the last 3 months 0.12% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 32/109 (-1) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateAug 16, 2024
Dividend/Share
₹18.00
Ex DateEx Date
Aug 16, 2024
Cash Dividend
Ex DateEx DateApr 20, 2023
Dividend/Share
₹18.00
Ex DateEx Date
Apr 20, 2023
Cash Dividend
Ex DateEx DateMay 11, 2022
Dividend/Share
₹15.00
Ex DateEx Date
May 11, 2022
Cash Dividend
Ex DateEx DateJun 17, 2021
Dividend/Share
₹15.00
Ex DateEx Date
Jun 17, 2021
Cash Dividend
Ex DateEx DateNov 12, 2020
Dividend/Share
₹10.00
Ex DateEx Date
Nov 12, 2020
Thyrocare Technologies announced the cessation of Neetin Shivajirao Desai (DIN No: 02622364) as Independent Director of the company with effect from 19 September 2024 on completion of second term. Powered by Capital Market - Live
Thyrocare Technologies said that it shall have access to 11 centres of Vimta Labs at the locations such as Telangana, Andhra Pradesh, Uttar Pradesh and Odisha. The central processing laboratory, which is also a National Accreditation Board for Testing and Calibration Laboratories (NABL) accredited laboratory, is situated in Hyderabad, it added. Vimta Labs through its diagnostic and pathological services business has recorded a revenue of Rs 30 crore during FY 2024 and Rs 7 Crore in Q1 FY 2025. The company added that the completion of the acquisition is subject to fulfilment of the conditions precedent. Rahul Guha, MD & CEO, Thyrocare Technologies, said, 'This strategic move aligns with our growth objectives, allowing Thyrocare to expand its market share, solidify our leadership position in South India, and grow our business with franchisees and hospitals. Additionally, this expansion will enable Thyrocare to leverage the benefits of scale.' Thyrocare Technologies is engaged in the healthcare industry and is involved in providing quality diagnostic services at affordable costs to patients, laboratories and hospitals in India. Vimta Labs is a leading contract research and testing services provider in India. Shares of Thyrocare Technologies shed 0.10% to Rs 864.05 while those of Vimta Labs slipped 2.24% to Rs 627.55 on the BSE. Powered by Capital Market - Live
Thyrocare Technologies has signed a Business Transfer Agreement for purchase of the diagnostic and pathological services business of Vimta Labs. Vimta Labs through its diagnostic and pathological services business has recorded a revenue of Rs 30 crore during FY 2024 and Rs 7 crore in Q1 FY 2025.Powered by Capital Market - Live
Thyrocare Technologies announced that the Annual General Meeting (AGM) of the company will be held on 23 August 2024.Powered by Capital Market - Live
Thyrocare expands Northern India presence with Polo Labs acquisition
Thyrocare Q1 Results Review - Margin Thesis Is Starting To Unfold: ICICI Securities
Gainers & Losers: Dabur, Avanti Feeds among 9 stocks in limelight on Wednesday
Thyrocare Technologies shares soar nearly 17% as Q1 results impress D-Street
Thyrocare Tech stock skyrockets 17% post Q1FY25 results; details here
The key equity indices traded with limited losses in the mid-afternoon trade. The Nifty traded below the 24,400 level after hitting the day's high of 24,504.25 in early trade. Financial services shares extended loss for the two consecutive trading sessions. At 14:30 IST, the barometer index, the S&P BSE Sensex, was down 358.86 points or 0.44% to 80,088.97. The Nifty 50 index declined 91 points or 0.37% 24,392.75. The broader market outperformed the headline indices. The S&P BSE Mid-Cap index rose 0.60% and the S&P BSE Small-Cap index added 1.60%. The market breadth was strong. On the BSE, 2,703 shares rose and 1,136 shares fell. A total of 120 shares were unchanged. Economy: Seasonally adjusted index, HSBC Flash India Composite Output Index rose from 60.9 in June to 61.4 at the start of the second fiscal quarter. Growth strengthened at goods producers and service providers, with the former leading the upturn, the strongest rate of expansion for three months. HSBC Flash India Manufacturing PMI stood at 58.5 in July as against 58.3 in June, signalling a historically strong improvement in the health of the sector. Anecdotal evidence suggested that favourable market conditions and new business gains underpinned the upturn in private sector activity. HSBC Flash India Services PMI Business Activity Index stood at 61.1 in July as compared with 60.5 in June while HSBC Flash India Manufacturing PMI Output Index increased to 62.2 in July from 61.9 in June. The latest results also revealed that rising material and labour costs added to inflationary pressures. In particular, selling prices rose to the greatest extent since February 2013. Pranjul Bhandari, Chief India Economist at HSBC, said: 'The Flash Composite Output Index signalled continued robust growth in India's private sector. The rise in output in July was led by a further increase in business activity in the manufacturing sector, while the pace of expansion in services output also accelerated and remained well above its long-run average. As a result, companies turned more optimistic in July, following a moderation in business confidence in June. We note that the rate of input cost inflation continued to trend higher in both sectors, which has driven firms to keep raising sales prices.' Buzzing Index: The Nifty Financial Services index fell 1.16% to 23,034.75. The index declined 2.50% in the two trading sessions. Bajaj Finserv (down 3.03%), Axis Bank (down 2.58%), Bajaj Finance (down 2.07%), Shriram Finance (down 1.72%) and State Bank of India (down 1.55%), Kotak Mahindra Bank (down 1.53%), HDFC Bank (down 1.29%), ICICI Bank (down 1.14%), Cholamandalam Investment & Finance Company (down 0.82%) and IDFC (down 0.77%) slipped. On the other hand, ICICI Prudential Life Insurance Company (up 7.57%) ,HDFC Life Insurance Company (up 3.61%) and LIC Housing Finance (up 2.41%) advanced. Numbers to Track: The yield on India's 10-year benchmark federal rallied 1.65% to 7.085 as compared with previous close 6.970. In the foreign exchange market, the rupee lower against the dollar. The partially convertible rupee was hovering at 83.7125, compared with its close of 83.6950 during the previous trading session. MCX Gold futures for 5 August 2024 settlement rose 0.42% to Rs 68,794. The US Dollar index (DXY), which tracks the greenback's value against a basket of currencies, was up 0.06% to 104.51. The United States 10-year bond yield shed 0.02% to 4.238. In the commodities market, Brent crude for September 2024 settlement added 59 cents or 0.73% to $81.60 a barrel. Stocks in Spotlight: Thyrocare Technologies zoomed 16% after the healthcare service provider reported 39.71% increase in consolidated net profit to Rs 24.17 crore in Q1 FY25 from Rs 17.30 crore posted in Q1 FY24. Revenue from operations grew by 16.32% year on year (YoY) to Rs 156.91 crore in the quarter ended 30 June 2024. Schaeffler India rallied 5.87% after the company reported 6.82% increase in standalone net profit to Rs 253.54 crore in Q2 CY24 as against Rs 237.2 crore posted in Q2 CY23. Revenue from operations jumped 13.27% year on year (YoY) to Rs 2,071.9 crore in Q2 CY24. Bajaj Finserv declined 2.53%. The company's consolidated net profit jumped 10.04% to Rs 2,137.70 crore on a 35.22% increase in total income to Rs 31,480.14 crore in Q1 FY25 over Q1 FY24.Powered by Capital Market - Live
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 7.06%, vs industry avg of 10.02%
Decreasing Market Share
Over the last 5 years, market share decreased from 1.13% to 0.94%
Lower than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of -3.63%, vs industry avg of 42.9%